Literature DB >> 31409572

Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson's disease patients: Results from the COPPADIS Study Cohort.

D Santos García1, T de Deus Fonticoba2, E Suárez Castro2, C Borrué3, M Mata3, B Solano Vila4, A Cots Foraster4, M Álvarez Sauco5, A B Rodríguez Pérez5, L Vela6, Y Macías7, S Escalante8, P Esteve8, S Reverté Villarroya8, E Cubo9, E Casas9, S Arnaiz9, F Carrillo Padilla10, M Pueyo Morlans10, P Mir11, P Martinez-Martin12.   

Abstract

OBJECTIVE: To identify factors related to a poor health-related and global quality of life (QoL) in a cohort of non-demented Parkinson's disease (PD) patients and compare to a control group.
METHODS: The data correspond to the baseline evaluation of the COPPADIS-2015 Study, an observational, 5-year follow-up, multicenter, evaluation study. Three instruments were used to assess QoL: (1) the 39-item Parkinson's disease Questionnaire (PDQ-39), (2) a subjective rating of global QoL (PQ-10), and (3) the EUROHIS-QOL 8-item index (EUROHIS-QOL8). Multiple linear regression methods were used to evaluate the direct impact of different variables on these QoL measures.
RESULTS: QoL was worse in PD patients (n = 692; 62.6 ± 8.9 years old, 60.3% males) than controls (n = 206; 61 ± 8.3 years old, 49.5% males): PDQ-39, 17.1 ± 13.5 vs 4.4 ± 6.3 (p < 0.0001); PQ-10, 7.3 ± 1.6 vs 8.1 ± 1.2 (p < 0.0001); EUROHIS-QOL8, 3.8 ± 0.6 vs 4.2 ± 0.5 (p < 0.0001). A high correlation was observed between PDQ-39 and Non-Motor Symptoms Scale (NMSS) (r = 0.72; p < 0.0001), and PDQ-39 and Beck Depression Inventory-II (BDI-II) (r = 0.65; p < 0.0001). For health-related QoL (PDQ-39), non-motor symptoms burden (NMSS), mood (BDI-II), and gait problems (Freezing Of Gait Questionnaire [FOGQ]) provided the highest contribution to the model (β = 0.32, 0.28, and 0.27, respectively; p < 0.0001); whereas mood and gait problems contributed the most to global QoL (PQ-10, β = -0.46 and -0.21, respectively; EUROHIS-QOL8, β = -0.44 and -0.23, respectively).
CONCLUSIONS: QoL is worse in PD patients than in controls. Mood, non-motor symptoms burden, and gait problems seem to be the most relevant factors affecting health-related and global perceived QoL in non-demented PD patients.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Gait; Mood; Motor fluctuations; Non-motor symptoms; Parkinson's disease; Quality of life

Mesh:

Year:  2019        PMID: 31409572     DOI: 10.1016/j.parkreldis.2019.07.031

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  22 in total

1.  The path linking excessive daytime sleepiness and activity of daily living in Parkinson's disease: the longitudinal mediation effect of autonomic dysfunction.

Authors:  Ying Huang; Sidan Du; Durong Chen; Yao Qin; Jing Cui; Hongjuan Han; Xiaoyan Ge; Wenlin Bai; Xinnan Zhang; Hongmei Yu
Journal:  Neurol Sci       Date:  2022-04-30       Impact factor: 3.830

2.  "Does the Response to Morning Medication Predict the ADL-Level of the Day in Parkinson's Disease?"

Authors:  Trine Hørmann Thomsen; Troels Wesenberg Kjær; Lene Bastrup Jørgensen; Anita Haahr; Kristian Winge
Journal:  Parkinsons Dis       Date:  2020-07-27

3.  Association of Motor and Nonmotor Symptoms With Health-Related Quality of Life in a Large Online Cohort of People With Parkinson Disease.

Authors:  Meredith A Bock; Ethan G Brown; Li Zhang; Caroline Tanner
Journal:  Neurology       Date:  2022-04-13       Impact factor: 11.800

4.  Cultural bias in motor function patterns: Potential relevance for predictive, preventive, and personalized medicine.

Authors:  Karen Otte; Tobias Ellermeyer; Masahide Suzuki; Hanna M Röhling; Ryota Kuroiwa; Graham Cooper; Sebastian Mansow-Model; Masahiro Mori; Hanna Zimmermann; Alexander U Brandt; Friedemann Paul; Shigeki Hirano; Satoshi Kuwabara; Tanja Schmitz-Hübsch
Journal:  EPMA J       Date:  2021-03-03       Impact factor: 6.543

5.  Impact of subthreshold depression on health-related quality of life in patients with Parkinson's disease based on cognitive status.

Authors:  Aline Schönenberg; Hannah M Zipprich; Ulrike Teschner; Julian Grosskreutz; Otto W Witte; Tino Prell
Journal:  Health Qual Life Outcomes       Date:  2021-03-25       Impact factor: 3.186

6.  Staging Parkinson's Disease Combining Motor and Nonmotor Symptoms Correlates with Disability and Quality of Life.

Authors:  D Santos García; T De Deus Fonticoba; J M Paz González; C Cores Bartolomé; L Valdés Aymerich; J G Muñoz Enríquez; E Suárez; S Jesús; M Aguilar; P Pastor; L L Planellas; M Cosgaya; J García Caldentey; N Caballol; I Legarda; J Hernández Vara; I Cabo; L López Manzanares; I González Aramburu; M A Ávila Rivera; M J Catalán; V Nogueira; V Puente; J M García Moreno; C Borrué; B Solano Vila; M Álvarez Sauco; L Vela; S Escalante; E Cubo; F Carrillo Padilla; J C Martínez Castrillo; P Sánchez Alonso; M G Alonso Losada; N López Ariztegui; I Gastón; J Kulisevsky; M Blázquez Estrada; M Seijo; J Rúiz Martínez; C Valero; M Kurtis; O de Fábregues; J González Ardura; C Ordás; L López Díaz; P Mir; P Martinez-Martin
Journal:  Parkinsons Dis       Date:  2021-05-13

7.  Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson's Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up.

Authors:  Diego Santos-García; Teresa de Deus; Carlos Cores; Hector Canfield; Jose M Paz González; Cristina Martínez Miró; Lorena Valdés Aymerich; Ester Suárez; Silvia Jesús; Miquel Aguilar; Pau Pastor; Lluis Planellas; Marina Cosgaya; Juan García Caldentey; Nuria Caballol; Ines Legarda; Jorge Hernández-Vara; Iria Cabo; Lydia López Manzanares; Isabel González Aramburu; Maria A Ávila Rivera; Maria J Catalán; Victor Nogueira; Victor Puente; Julio Dotor; Carmen Borrué; Berta Solano; Maria Álvarez Sauco; Lydia Vela; Sonia Escalante; Esther Cubo; Francisco Carrillo; Juan C Martínez Castrillo; Pilar Sánchez Alonso; Gemma Alonso; Nuria López Ariztegui; Itziar Gastón; Jaime Kulisevsky; Marta Blázquez; Manuel Seijo; Javier Rúiz Martínez; Caridad Valero; Monica Kurtis; Oriol de Fábregues; Jessica Ardura; Ruben Alonso; Carlos Ordás; Luis M López Díaz; Darrian McAfee; Pablo Martinez-Martin; Pablo Mir
Journal:  J Pers Med       Date:  2021-06-30

8.  Safinamide Improves Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study.

Authors:  Diego Santos García; Carmen Labandeira Guerra; Rosa Yáñez Baña; Maria Icíar Cimas Hernando; Iria Cabo López; Jose Manuel Paz Gonález; Maria Gemma Alonso Losada; María José González Palmás; Cristina Martínez Miró
Journal:  Brain Sci       Date:  2021-03-02

9.  Diplopia Is Frequent and Associated with Motor and Non-Motor Severity in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up.

Authors:  Diego Santos García; Lucía Naya Ríos; Teresa de Deus Fonticoba; Carlos Cores Bartolomé; Lucía García Roca; Maria Feal Painceiras; Cristina Martínez Miró; Hector Canfield; Silvia Jesús; Miquel Aguilar; Pau Pastor; Marina Cosgaya; Juan García Caldentey; Nuria Caballol; Inés Legarda; Jorge Hernández Vara; Iria Cabo; Lydia López Manzanares; Isabel González Aramburu; María A Ávila Rivera; Víctor Gómez Mayordomo; Víctor Nogueira; Víctor Puente; Julio Dotor; Carmen Borrué; Berta Solano Vila; María Álvarez Sauco; Lydia Vela; Sonia Escalante; Esther Cubo; Francisco Carrillo Padilla; Juan C Martínez Castrillo; Pilar Sánchez Alonso; Maria G Alonso Losada; Nuria López Ariztegui; Itziar Gastón; Jaime Kulisevsky; Marta Blázquez Estrada; Manuel Seijo; Javier Rúiz Martínez; Caridad Valero; Mónica Kurtis; Oriol de Fábregues; Jessica González Ardura; Ruben Alonso Redondo; Carlos Ordás; Luis M López Díaz; Darrian McAfee; Pablo Martinez-Martin; Pablo Mir
Journal:  Diagnostics (Basel)       Date:  2021-12-17

10.  The Impact of COVID-19 Pandemic on Disease Severity and Quality of Life in Parkinson's Disease.

Authors:  Alvee Saluja; Jasmine Parihar; Divyani Garg; Rajinder K Dhamija
Journal:  Ann Indian Acad Neurol       Date:  2021-04-05       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.